Interim guidance 2 march 2021
Current use of drugs to prevent COVID-19 is variable, reflecting large-scale uncertainty. Numerous randomized trials of many different drugs are underway to inform practice. This first version of the Drugs to prevent COVID-19: A WHO living guideline contains new inform...ation and a recommendation on hydroxychloroquine. It follows the publication of six trials synthesized in a living network meta-analysis (NMA).
more
If you have had COVID-19, should you still get vaccinated ? Why are we not vaccinating children under 16? WHO’s Chief Scientist Dr Soumya Swaminathan explains these and other vaccine related questions in Science in 5 this week.
How far apart should the doses of vaccines be? What if I miss my second dose? Can I get two doses from two different manufacturers? How was safety of vaccines ensured? WHO’s Chief Scientist, Dr Soumya Swaminathan explains in Science in 5.
This checklist helps to identify the necessary measures to be implemented to mitigate infection transmission among travellers and ground-crossing staff in the context of the COVID-19 pandemic. It features key questions and considerations for gauging the capacity of responding to COVID-19 transmissio...n risks and informing on reducing them at and around ground crossings. It does so in the form of a structured questionnaire. The guidance will have particular relevance for National International Health Regulations Focal Points and competent authorities at the point of entry, including relevant representatives of ground crossing authority/ies of the country such as public health authorities, and representatives from other sectors, including law enforcement, customs and migration.
more
This updated glossary for malaria aims to improve communication and mutual understanding within the scientific community, as well as with funding agencies, public health officials responsible for malaria programmes, and policy-makers in malaria-endemic countries
How concerned should we be about the new variants of SARS CoV 2 which cause COVID-19? Is it unusual for viruses to change and mutate? Do vaccines protect against these variants and what can you do to protect yourself? WHO’s Chief Scientist Dr Soumya Swaminathan explains in Science in 5
This visual guide provides an overview of the various means of support WHO offers to member states to advance climate-resilient health. The guide offers answers to key questions to understand WHO's support to countries on climate change and health, including: What are the impacts of climate change o...n health and the potential health co-benefits of climate change mitigation? How do we develop comprehensive plans and strategies to address climate-sensitive health risks and build climate-resilient health systems and facilities?
How do we access climate financing for climate change and health, including the Green Climate Fund (GCF) Readiness programme? What interventions can be implemented to address climate-sensitive health risks and strengthen the resilience and environmental sustainability of health systems and facilities? How do we monitor progress made at national level on climate change and health?
more
If you have been wondering when you would receive your vaccine? Why you should get vaccinated and are concerned about what your are hearing about side effects, this episode of Science with 5 with WHO’s Chief Scientist Dr Soumya Swaminathan is for you.
What do we know about the Delta variant so far? How can we assess our risk? What strategies should we apply to protect ourselves whether we are in a low vaccination or high vaccination setting? WHO’s Dr Maria Van Kerkhove explains in Science in 5.
In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems’ ability to prov...ide population-wide access to essential medicines.
Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products.
This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.
more
The WHO Global Learning Laboratory (GLL) for Quality UHC links the experiences, expertise, and wisdom of people across the world on important issues relating to quality in the context of UHC. The GLL is a safe space to share knowledge, experiences and ideas; to challenge ideas and approaches; and to... spark new thinking for quality UHC
more
Now the world is getting closer to a vaccine for COVID-19, how will these vaccines reach you?
WHO’s Dr Katherine O’Brien explains COVID-19 vaccine distribution in Science in 5.
The WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination is intended to offer guidance on the prioritization of groups for vaccination when vaccine supply is limited. It provides a values foundation for the objectives of COVID-19 vaccination programmes and links t...hose to target groups for vaccination. This information is valuable to countries and globally while specific policies will be developed once vaccines become available.
This document it available in Arabic, Chinese and Russian
more
As vaccines get approved by national authorities, learn about National and WHO approval processes for vaccines and how safety is ensured during emergency approval of vaccines. Dr Mariângela Simão explains in Science in 5.